CTOs on the Move

Refuge Biotechnologies

www.refugebiotech.com

 
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Refuge Biotechnologies raised $25M on 05/02/2018

Similar Companies

Ecovative Design

Ecovative uses biology to solve fundamental human needs at industrial scales and in consumer applications. Ecovative uses mycelium to grow category defining products ranging from leather like textiles to sustainable packaging to high performance foams for apparel and beauty.

Alpine Biomed

Alpine Biomed is a Fountain Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

NOVOS

NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.

Senda Biosciences

Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda`s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.